Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3954959 A
Publication typeGrant
Application numberUS 05/608,230
Publication dateMay 4, 1976
Filing dateAug 27, 1975
Priority dateMar 28, 1973
Publication number05608230, 608230, US 3954959 A, US 3954959A, US-A-3954959, US3954959 A, US3954959A
InventorsArne Martinus Pedersen
Original AssigneeA/S Alfred Benzon
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Coated particles, slow release
US 3954959 A
Oral drug preparations are described, having a protracted effect and a suitable rate of release of the drug during its period of action, said preparations comprising a pharmaceutically active component to which has been admixed one or more buffers, and possibly other pharmaceutically acceptable adjuvants, the mixture having been shaped into small particles and subsequently been coated with a film-forming material allowing for diffusion of stomach juice and intestinal juice together with the drugs dissolved therein, but not being soluble in the said juices.
Previous page
Next page
I claim:
1. An oral drug preparation having a protracted effect and a substantially constant rate of release of the drug, comprising an admixture, of a drug and an effective amount of a buffer acid, buffer acid salts, and mixtures thereof, in the form of small spheroidal particles of 0.1 to 5 mm diameter, said particles having a coating thereon of a film-forming acrylic polymer drug-diffusing dragee lacquer, allowing for diffusion of the stomach and intestinal juices through the coating, but not being soluble in said juices.

This application is a continuation-in-part of my application Ser. No. 453,032, filed Mar. 20, 1974.

The present invention relates to new oral drug preparations having a protracted effect and a suitable rate of release of the active component during the period of action.

The oral drug preparations of the invention comprise an active component, possibly admixed with pharmaceutically acceptable adjuvants, which has been shaped into small spheroidal particles, and subsequently coated with a film-forming material allowing for diffusion of stomach juice and intestinal juice together with drugs dissolved therein, but not being dissolved by the said juices.

While passing through the human digestive tract, orally administered drugs are subjected to pH-values varying from 1.0 to 7.4. Thus the saliva of the mouth has a pH of 7, the stomach juice of a fasting person has normally a pH of 1, which may vary between 1.0 and 4.0 pursuant to consumption of food, bile has pH 7.0 to 7.4, and in the intestines pH is 5 to 7.

Moreover, the orally taken drug stays for varying periods in the individual parts of the digestive tract.

Together with the fact that the solubility of many drugs is dependent upon the pH of the solvent medium this results in making it extremely difficult to obtain even approximately the same rate of release everywhere in the digestive tract, even if attempts in this respect have not been missing.

Thus, it has been proposed to use combinations of coatings which are soluble in the stomach juice and the intestinal juices, respectively. By producing a tablet, for example, by first coating a smaller tablet of the active substance with a layer of a material not soluble in the stomach juice, but soluble in the intestine juices, and then depositing a layer of the active substance upon this coating, which is again coated with a layer of a material soluble in the stomach juice, part of the active substance will be released in the stomach, the remainder being released in the intestines. Thus, the period of action can be prolonged, but the release takes place in portions and owing to the pH dependent solubility of the coatings, the released drug will be available for different periods from time to time.

Better results have been achieved by using coatings of various synthetic polymers which have been modified by means of solubilizing groups, e.g. quaternary ammonium groups. Thus, it is possible to produce coatings, the solubility and the permeability of which are independent of the physiological pH within the range 2-8, since by carefully adjusting the content of quaternary ammonium groups to a low value, it is possible to obtain coatings being insoluble, but to some extent swelling in water. In principle, such coatings function in the way that stomach juice or intestinal juice diffuses in or out through the coating, gradually dissolving the active substance.

More recently, the efforts have been directed to finding suitable combinations of polymers in order to control the diffusion rate and thereby the release of the coated active substance, cf. the U.S. Pat. No. 3,775,537.

Even if it is maintained that a pH independent release of the enclosed drugs can be obtained by means of these coatings, experiments have shown, however, that this is not always so and that often individual adjustment of the properties of the coating is necessary, when the active substance is replaced by another active substance.

It is an object of the present invention to provide drug preparations of the said kind in the form of small spheroidal particles having a coating thereon of a film-forming acrylic polymer drug-diffusing dragee lacquer, which without any individual adjustment of the coating ensures a pH independent release of the active substance at a substantially constant rate.

This is accomplished, according to the invention, by the addition to the material, from which the particles are prepared, of a buffer or mixture of buffers which is so chosen, dependent upon the kind of active substance, that a suitable pH is obtained for dissolving said active substance in the body fluid permeating the coating.

By thus ensuring release of the active substance at constant pH irrespective of the ambient pH, there is no need for adjustment of the properties of the coating after the kind of active substance in the preparation, so that the same composition of the coating used for any kind of active substance will give a substantially constant rate of release. Changes in the thickness of the applied coating, or in the composition of the coating thus only serves to control the amount of released active substance per unit of time.

Thus, any of the commercially available acrylic polymer film-forming dragee lacquers may be used for the coating of the present drug preparations, but at present the dragee lacquers marketed by Rohm Pharma GmbH, Darmstadt, German Federal Republic, under the registered trade name EUDRAGIT, and of compositions as described in the U.S. Pat. No. 3,775,537, are preferred, possibly with admixed plasticizer.

The buffer or mixture of buffers is chosen, having regard to the stability and solubility also of the other components of the preparation, so as to impart a pH-value from 1 to 7.5, preferably from 4 to 6, to the buffered system.

The buffers to be used should be physiologically acceptable and could be e.g. primary, secondary, or tertiary salts of phosphoric acid, or salts of phthalic acid, citric acid, tartaric acid, or salts of amino acids, e.g. glycine, or mixtures of the said buffer salts.

The amount of buffer must be sufficient to ensure a buffer effect during the time it takes for the drug to be released from the composition particles. Thus, the proportion of buffer to drug will be dependent on the rate of diffusion of both through the coating material, and is easily determined by simple tests for a given combination of drug, buffer and coating material.

The diameter of the spheroidal particles will generally be from 0.1 to 5 mm, preferably 0.5 to 1.5 mm.

The mode of action of the compositions obtained in this manner is as follows:

The fluids in the digestive tract, e.g. stomach juice and intestine juice, can penetrate through the coating, acting as a diffusion membrane. The fluid thus passing through the coating into the interior of the particles will dissolve the buffer and thus get a pH suitable for dissolving and possibly ionizing the drug to create a solution of it in equilibrium with solid matter. Owing to the differences in concentration on the inner and outer sides of the membrane, the said solution will diffuse out into the surrounding body fluid, and further fluid will pass in so that a slow, substantially constant release of the drug takes place, and this will be independent of the pH of the body fluid proper.

An additional advantage is as hereinbefore mentioned that an adjustment of the coating composition to the kind of drug used becomes unnecessary, since instead the drug is adjusted by means of the buffer which is by far easier than an adjustment of the composition of the coating to the individual drugs.

The drugs, which may be used in the preparations of the invention, may be of acid as well as of basic or neutral character in solution. As examples of the former may be mentioned valeric acid, ascorbic acid, 1-(m-trifluoromethylphenyl)-2-(N-ethylamino)-propane, HCl, and barbituric acids, whereas ephedrine, atropine, pyridoxine, and codeine are examples of drugs of basic character, and reserpine and theophylline are examples of drugs forming neutral solutions.

The following experiment is illustrative of the effect obtained by the preparations of the invention.

In the experiment a coating composition consisting of the following ingredients was used:

                      Parts by Weight______________________________________Acrylic polymer (12.5% solution in iso-propanol-acetone (3:2)) 50Pigment                 0.667Talc                    9.833Acetyltributyl citrate  0.74Isopropanol ad          100______________________________________

With this composition, two lots of cores A and B withouth and with buffer, respectively, were coated, the compositions of A and B in parts by weight being as follows:

1-(m-Trifluoromethylphenyl)-2-(N-ethylamino)-propane,HCl                  40.0       40.0Saccharose             38.0       17.0Microcrystalline cellulose                  20.0       20.0Hydroxypropyl cellulose                   2.0        3.0Monosodium phosphate   --         20.0

The release of the drug in synthetic stomach juice and intestinal juice having a pH of 1.5 to 7.2, respectively, was determined periodically. The results are given in the following table, the figures representing the weight percent of the total content of the drug, which was released within the stated period.

__________________________________________________________________________      Percent by weight released after hoursComposition  pH  1    2    3  4   5  6   7  8__________________________________________________________________________A      1.5 10   17   20 36  42 88  92 --B      1.5 3.5  7    --  13.5                       --  24.5                              --  45.5A      7.2 3.5  8    15 22  40 77  87 --B      7.2 4    6.5  -- 11  -- 22  -- 45__________________________________________________________________________

The table shows that the release of the drug of composition B is proportional to the time and independent of the pH.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2971889 *Mar 18, 1958Feb 14, 1961Smith Kline French LabPress coated enteric tablets and process for preparing them
US3247066 *Sep 12, 1962Apr 19, 1966Parke Davis & CoControlled release dosage form containing water-swellable beadlet
US3538214 *Apr 22, 1969Nov 3, 1970Merck & Co IncControlled release medicinal tablets
US3577512 *Oct 11, 1968May 4, 1971Nat Patent Dev CorpSustained release tablets
US3608063 *Aug 15, 1969Sep 21, 1971Banker Gilbert SMolecular drug entrapment process and compositions
US3629393 *Sep 11, 1969Dec 21, 1971Nikken Chemicals Co LtdRelease-sustaining-tablet
US3641237 *Sep 30, 1970Feb 8, 1972Nat Patent Dev CorpZero order release constant elution rate drug dosage
US3689634 *Sep 23, 1970Sep 5, 1972Ceskoslovenska Akademie VedProtracted activity oral hydrogel bead
US3775537 *Jun 18, 1971Nov 27, 1973Roehm GmbhCopolymer coatings for pharmaceuticals
Non-Patent Citations
1 *Lehmann, K. et al. Drugs Made Ger. 16(4): 126, 131-132, 134, 136 (1973) Use of Aqueous Synthetic-Polymer Dispersions for Coating Pharmaceutical Dosage Forms.
2 *Lehmann, K. et al. Labo-Pharma-Probl. Tech. 22 (228): 57-62, 65 (1974) Use of Aqueous Plastic Dispersions for Coating Pharmaceutical Forms.
3 *Lehmann, K. et al. Pharm. Ind. 31(5): 319-322 (1969) Permeable Acrylic Resin Lacquers for Production of Medicinal Depot Forms II. (1).
4 *Lehmann, K. et al. Pharm. Ind. 31(6): 409-412 (1969) Permeable Acrylic Resin Lacquers for Production of Medicinal Depot Forms II. (2).
5 *Lehmann, K. Mfg. Chem. Aerosol News. 45(5): 48, 50 (1974) Polymer Coating of tablets. Versatile Technique.
6 *Lehmann, K. Pharm. Ind. 29(6): 396-398 (1967) Acrylic Resin Lacquers for Preparation of Depot Medicinal Forms.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4223008 *May 14, 1979Sep 16, 1980John Wyeth & Brother LimitedSlow release pharmaceutical compositions containing 3-[2-(4-benzamido-1-piperidyl)ethyl]indole, embonate
US4229428 *Apr 5, 1979Oct 21, 1980Cherqui Jean SGalenical form of administration of betahistine and its derivatives
US4261971 *Dec 17, 1979Apr 14, 1981Aktiebolaget HassleAnionic polymer which is soluble or insoluble, depending on ph
US4263273 *Dec 17, 1979Apr 21, 1981Aktiebolaget AstraPharmaceutical preparation comprising a cardiac glycoside with a polymer coating
US4367217 *Dec 31, 1980Jan 4, 1983Boehringer Ingelheim GmbhDipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
US4370313 *Oct 26, 1981Jan 25, 1983Eaton Laboratories, Inc.Nitrofurantoin dosage form
US4557925 *Sep 5, 1984Dec 10, 1985Ab FerrosanMembrane-coated sustained-release tablets and method
US4562061 *Mar 27, 1985Dec 31, 1985Aktiebolaget HasslePharmaceutical preparation
US4609542 *Jul 1, 1985Sep 2, 1986Elan Corporation, P.L.C.New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4629619 *Sep 19, 1985Dec 16, 1986Ab FerrosanConstant dissolution rate
US4629620 *Sep 19, 1985Dec 16, 1986Ab FerrosanPolyvinyl chloride, polyvinyl acetate, polyvinyl alcohol terpolymer
US4724148 *Nov 14, 1986Feb 9, 1988Yamanouchi Pharmaceutical Co., Ltd.Amosulalol hydrochloride long acting formulation
US4747845 *Jan 3, 1986May 31, 1988Enquay Pharmaceutical AssociatesSynthetic resin matrix system for the extended delivery of drugs
US4749575 *Jan 29, 1986Jun 7, 1988Bio-Dar Ltd.Microencapsulated medicament in sweet matrix
US4758437 *Feb 11, 1987Jul 19, 1988Yamanouchi Pharmaceutical Co., Ltd.Composition for long acting nicardipine preparation and process of producing the composition
US4765988 *May 5, 1987Aug 23, 1988Yamanouchi Pharmaceutical Co., Ltd.Amosulalol hydrochloride long acting formulations
US4863741 *Jan 30, 1989Sep 5, 1989Abbott LaboratoriesErythromycin, protective coatings, antibiotics
US4874614 *Jan 30, 1989Oct 17, 1989Abbott LaboratoriesImproved impact strength for resisting compression and packaging stress by including microcrystalline cellulose in the matrix
US4940588 *Mar 17, 1988Jul 10, 1990Elan CorporationControlled release powder and process for its preparation
US4952402 *Mar 17, 1988Aug 28, 1990Elan Corporation, P.L.C.Edible taste-masked drugs; micromatrix active material coated with nontoxic polymer; liquids; tablets
US4966768 *Nov 7, 1988Oct 30, 1990American Home Products CorporationSustained release etodolac
US5051262 *Nov 18, 1986Sep 24, 1991Elan Corp., P.L.C.Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
US5320853 *Dec 22, 1992Jun 14, 1994Merrell Dow Pharmaceuticals Inc.Controlled release formulation for pharmaceutical compounds
US5541170 *Mar 10, 1995Jul 30, 1996Tillotts Pharma AgOrally administrable pharmaceutical compositions
US5541171 *May 23, 1995Jul 30, 1996Tillotts Pharma AgOrally administrable pharmaceutical composition
US6090411 *Mar 9, 1998Jul 18, 2000Temple UniversityMonolithic tablet for controlled drug release
US6106862 *Aug 13, 1998Aug 22, 2000Andrx CorporationOnce daily analgesic tablet
US6177102Dec 2, 1999Jan 23, 2001Andrx Pharmaceuticals, Inc.Controlled release dosage form of analgesic such as etodolac, filler, and a carrier base comprising a high molecular weight hydroxypropyl methyl cellulose, optional water insoluble binder, and remainder water soluble binder
US6274171Jan 20, 2000Aug 14, 2001American Home Products CorporationAntidepressant; Side effect reduction of nausea and vomiting
US6403120Sep 12, 2001Jun 11, 2002WyethExtended release formulation of venlafaxine hydrochloride
US6419958Jun 19, 2001Jul 16, 2002WyethExtended release formulation of venlafaxine hydrochloride
US6743444Jul 3, 2001Jun 1, 2004Microbiological Research AuthorityMethod of making microencapsulated DNA for vaccination and gene therapy
US8133506Sep 12, 2008Mar 13, 2012Aptalis Pharmatech, Inc.Drug delivery systems comprising weakly basic drugs and organic acids
EP0211991A1 *Aug 23, 1985Mar 4, 1987Ab LeoSubstained release tablets and method for preparation thereof
EP0309157A1 *Sep 16, 1988Mar 29, 1989American Home Products CorporationSustained release etodolac
U.S. Classification424/497
International ClassificationA61K9/16, A61K9/22, A61K9/50
Cooperative ClassificationA61K9/5026, A61K9/5047, A61K9/1611
European ClassificationA61K9/50H6F2B, A61K9/50H6B, A61K9/16H2